Public announcements.
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
Levant Capital and its affiliates complete investment in IRRAS and acquire control of the listed medical device company
Levant Capital and its affiliates complete investment in IRRAS and acquire control of the listed medical device company
Levant Capital completes sale of USD 40m of interests in regional Papa Johns franchisee
Levant Capital has sold USD 39,500,000 of LP interests in PJ GCC Holdings in a secondary sale to new limited partners. PJ GCC Holdings is Levant Capital’s Papa Johns restaurant franchise business with exclusivity over the UAE, Saudi Arabia and other markets, and with over 80 restaurants operating currently.
Levant Capital completes sale of regional packaged foods business to listed Saudi conglomerate Savola Group for USD 260 million
In a regional marquee transaction, Levant Capital completes the strategic sale of Bayara to regional food giant Savola Group, after a three year hold period
Shoreline Biosciences Announces $140M Financing to Advance Pipeline of Next Generation Cellular Immunotherapies
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.
ShouTi Secures $100 Million Series B Financing
Stork Capital Participates in $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
Stork and Levant Capital Expand Private Client Services Teams with Senior Hires
In an article published this week, Bloomberg covers our recent key hires in Dubai and in Geneva
Kite and Shoreline Biosciences enter into strategic partnership to develop novel Allogeneic Cell Therapies
Following Kite's participation in the Series A round closed in March 2021, Kite (a Gilead Company - Nasdaq: GILD) and Shoreline enter into a strategic partnership, with a $60 million upfront payment and milestones and royalties payments worth up to $2.3 billion. Shoreline Biosciences was founded and seeded by Stork Capital in July 2020
Shoreline Biosciences and BeiGene Announce Strategic Collaboration
Following the seed round funding by Stork Capital in July 2020, and the $43m Series A round closed in March 2021, Shoreline Biosciences announces its first major partnership.
Stork Capital Backs Connect Biopharama
Connect Biopharma lists on NASDAQ raising US$191.3m
Shoreline Biosciences Announces $43m Financing
Co-founded by Stork Capital and led by Stork Capital’s Life Sciences Chairman Kleanthis G. Xanthopoulos, Ph.D.